Provided by Tiger Fintech (Singapore) Pte. Ltd.

Bristol-Myers Squibb

46.88
-0.7400-1.55%
Post-market: 46.940.0588+0.13%17:32 EDT
Volume:22.41M
Turnover:1.05B
Market Cap:95.40B
PE:17.55
High:47.40
Open:47.00
Low:46.52
Close:47.62
Loading ...

Is Bristol Myers Squibb's High-Yielding Dividend Safe?

Motley Fool
·
02 Apr

RBC Canadian Equity Income Fund's Strategic Move: Alimentation Couche-Tard Inc. Takes Center Stage

GuruFocus.com
·
02 Apr

Bristol Myers Squibb Co. Stock Outperforms Competitors Despite Losses On The Day

Dow Jones
·
02 Apr

The FDA Is 'Finished' as Firings Sweep Health Agencies. Drug Stocks Are Falling. -- Barrons.com

Dow Jones
·
02 Apr

Will Bristol Myers (BMY) Beat Estimates Again in Its Next Earnings Report?

Zacks
·
02 Apr

Is Bristol-Myers Squibb (BMY) One of the Best Healthcare Stocks to Buy According to Billionaires?

Insider Monkey
·
01 Apr

Beat the S&P 500 With This Cash-Gushing Dividend Stock

Motley Fool
·
01 Apr

Bristol Myers Squibb Co. Stock Outperforms Competitors On Strong Trading Day

Dow Jones
·
01 Apr

Bristol-Myers Squibb Company (BMY): Among the Best High Yield Stocks to Buy in April for Dividend Capture

Insider Monkey
·
01 Apr

Jim Cramer on Bristol-Myers Squibb. Co (NYSE:BMY): They Should Have Known Better

Insider Monkey
·
29 Mar

Trump nominees disclose US law firm pay

Reuters
·
29 Mar

Bristol Myers Squibb Co. Stock Outperforms Competitors On Strong Trading Day

Dow Jones
·
29 Mar

Bristol-Myers Squibb (NYSE:BMY) Sees Rising Interest in Sotyktu Despite 3% Share Price Dip

Simply Wall St.
·
29 Mar

BRIEF-Bristol Myers Squibb Receives Positive CHMP Opinion For The Subcutaneous Formulation Of Opdivo® (Nivolumab) Across Multiple Solid Tumor Indications

Reuters
·
28 Mar

Bristol Myers Gets CHMP Backing for Subcutaneous Opdivo

Dow Jones
·
28 Mar

Bristol Myers Squibb Receives Positive Chmp Opinion for the Subcutaneous Formulation of Opdivo® (Nivolumab) Across Multiple Solid Tumor Indications

THOMSON REUTERS
·
28 Mar

Bristol-Myers Squibb Co - EU Decision on Opdivo Marketing Authorization Expected by June 2, 2025

THOMSON REUTERS
·
28 Mar

Bristol Myers Squibb Receives Positive CHMP Opinion for the Subcutaneous Formulation of Opdivo® (nivolumab) Across Multiple Solid Tumor Indications

Business Wire
·
28 Mar

Ema's Chmp: for Opdivo, Recommended a New Pharmaceutical Form and New Strength for Subcutaneous Administration

THOMSON REUTERS
·
28 Mar

FDA Expands Exelixis Cabometyx Label for Neuroendocrine Tumors

Zacks
·
28 Mar